| Literature DB >> 31991678 |
Jingou Liang1, Xinyu Peng1, Xuedong Zhou1, Jing Zou1, Lei Cheng1.
Abstract
The oral cavity is a unique complex ecosystem colonized with huge numbers of microorganism species. Oral cavities are closely associated with oral health and sequentially with systemic health. Many factors might cause the shift of composition of oral microbiota, thus leading to the dysbiosis of oral micro-environment and oral infectious diseases. Local therapies and dental hygiene procedures are the main kinds of treatment. Currently, oral drug delivery systems (DDS) have drawn great attention, and are considered as important adjuvant therapy for oral infectious diseases. DDS are devices that could transport and release the therapeutic drugs or bioactive agents to a certain site and a certain rate in vivo. They could significantly increase the therapeutic effect and reduce the side effect compared with traditional medicine. In the review, emerging recent applications of DDS in the treatment for oral infectious diseases have been summarized, including dental caries, periodontitis, peri-implantitis and oral candidiasis. Furthermore, oral stimuli-responsive DDS, also known as "smart" DDS, have been reported recently, which could react to oral environment and provide more accurate drug delivery or release. In this article, oral smart DDS have also been reviewed. The limits have been discussed, and the research potential demonstrates good prospects.Entities:
Keywords: drug delivery systems; oral infectious diseases; stimuli-responsive DDS
Year: 2020 PMID: 31991678 PMCID: PMC7038021 DOI: 10.3390/molecules25030516
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Carriers of drug delivery systems(DDS) and the application in oral infectious diseases.
| Types of Carriers | Application Oral Diseases | Composition | |
|---|---|---|---|
| micro/nano | micro/nano sphere | dental caries [ | PLGA, PDLLA, PEG and biopolymers like lipid, chitosan, pectin, and alginate |
| nanofiber | periodontitis [ | ||
| nano capsule | dental resin modification [ | ||
| hydrogel | dental caries [ | Hydrophilic groups such as –OH, –CONH–, –CONH2– | |
| dendrimer | dental caries [ | PAMAM, poly(aryl ether) | |
Figure 1Examples of the structures of different kinds of carriers.
Figure 2Recent anti-bacterial DDS for dental caries. (a) chlorhexidine loaded mesoporous nanoparticles; (b) peptides loaded lipid-based nanoparticle; (c) chlorhexidine loaded ethy cellulose matrix varnish.
Figure 3Recent remineralizing DDS for dental caries. (a) Flouride loaded chitosan-based nanoparticles; (b) Triclosan-loaded PAMAM dendrimer. The dual functional DDS showed anti-bacterial effect and dental remineralization as well. Triclosan is an anti-bacterial agent while PAMAM dendrimers could aggregate into a microribbon structure and promote dental remineralization.
Figure 4Recent DDS for secondary caries. (a) Nanoparticles loaded restoration resin. Adhesives and composite resin could be loaded with anti-bacterial nanoparticle (such as Ag and ZnO) and remineralizating agents like Nano-ACP. (b) Indonmethacin-loaded lipid-based nano capsules modified dental adhesives. The nano capsules could release from the adhesives with sustained release of indomethacin which had anti-inflammatory effect on dental pulp.
Local DDS in periodontitis.
| Devices | Polymers * | Drug | Suistained |
|---|---|---|---|
| fibers | PLGA 1,GT 2 [ | tetracycline | 75 days |
| biodegradable | metronidazole or | over 7 days | |
| rings/ | trimethylene | doxycycline hyclate | 28 days |
| films | PEGylated rosin | sparfloxacin | over 21 days |
| Gelatin [ | curcumin | up to 7 days | |
| Chitosan [ | Metronidazole, | up to 7 days | |
| PEO 6, PDLLA 7 [ | Lipoxin A4 | 48h | |
| chitosan, PVA [ | doxycyclin | over 1 week | |
| in situ gel/ | PLGA, NMP 8 [ | Minocycline | over 48 h |
| Pluronic F127, | curcumin | over 1 week | |
| Pluronic, | meloxicam or | 3 days for MH, | |
| Cholesterol, | doxycycline hyclate | 10 days | |
| NMP, Ethylcellulose, | NMP | / | |
| mPEG-PDLLA [ | tinidazole | 192 h | |
| Carbopol 934P, | ketoprofen | over 24 h | |
| PLGA, calcium phosphate | BMP-2, FGF-2 | / | |
| PLGA, NMP [ | metronidazole | over 10 days | |
| micro-/ | BS 9, NMP, DMSO 10, | doxycycline hyclate | 47 days |
| PLGA [ | doxycycline hyclate | at least 15days | |
| Chitosan [ | clindamycin phosphate | more than 1 week | |
| PEG 12, PLA 13, | minocycline | 14 days | |
| Nanoparticles [ | tetracycline | over 5 days |
* The polymer carriers of DDS were showed in abbreviation: 1 PLGA: poly lactic glycolic acid; 2 GT: gum tragacanth; 3 TMC: trimethylene carbonate; 4 CL: caprolactone; 5 GL: glycolide; 6 PEO: poly(ethylene oxide; 7 PDLLA: poly(d,l-lactide); 8 NMP: N-methylpyrrolidone; 9 BS: Bleached shellac; 10 DMSO: dimethyl sulfoxide; 11 GMS: 2-pyrrolidone, glyceryl monostearate; 12 PEG: poly(ethylene glycol); 13 PLA: poly(lactic acid).
Figure 5DDS used in periodontitis. (a) antimicrobial agents loaded DDS. Various antibiotics (like metronidazole and levofloxacin) can be loaded in drug delivery devices, such as fibers and films. (b) DDS for immunomodulation and alveolar bone repair. Injectable drug delivery systems are commonly used devices, and anti-inflammation agents, bone repair factors and osteogenesis drugs are delivered. (c) DDS used in periodontitis with risk factors (such as smoking and diabetes).
Anti-bacterial DDS coating for the prevention of dental implantitis.
| Coating Type | Anti-bacterial Experiment Model * | Results | |
|---|---|---|---|
| Peptide | GL13K-peptide coated titanium [ | inhibited biofilm growth | |
| antimicrobial peptide OP-145 coated titanium [ | showed antimicrobial effect, sustained release for 30 days; prevented implant infections | ||
| Metal particles | AgNP-doped silica coated titanium [ |
| showed antibacterial effect for at least 7 days |
| zinc oxide and hydroxyapatite coated titanium [ | Human saliva biofilm model | showed antimicrobial effect; reduced facultatively anaerobic and | |
| metal nanoparticle incorporated glassy zirconia abutments [ | In vivo dog model | prevented biofilm formation and the peri-implant bone loss | |
| a combination of silver, titanium dioxide and hydroxyapatite nanocoatings [ |
| showed antimicrobial effect; healing. | |
| Ag-doped calcium deficient dydroxyapatite coated titanium [ | showed antibacterial effect and sustained release over 14 days | ||
| PLGA(Ag-Fe3O4)-coated dental implants [ |
| inhibited bacteria adherence | |
| Ag nanoparticles coated on titanium [ | showed antibacterial effect and sustained release for 7 days | ||
| Antibiotics | doxycycline-coated abutment surfaces [ |
| inhibited the bacterial growth; showed sustained release for least 2 weeks |
| Tetracycline-containing fibers coated titanium implant [ | showed inhibition of biofilm and kept releasing for 3 days | ||
| silica-gentamycin coated titanium implant [ |
| showed antibacterial effect and sustained release for 14 days | |
| Tetracycline loaded nanofibers coated titanium implant [ | Showed anti-bacterial effect | ||
| Tetracycline loaded titanium [ |
| showed antibacterial efficiency and sustained release for 15 days | |
| Cationic antibacterial agents | chlorhexidine hexametaphosphate nanoparticles coated titanium [ |
| demonstrated antibacterial effect and sustained release of soluble chlorhexidine for 99 days |
| The PIXIT implant containing polysiloxane oligomers and chlorhexidine gluconate [ | Clinic trail | controlled bacterial adhesion; reduced the bacterial species involved with long-term failure of dental implant | |
| Dimethylaminododecyl Methacrylate(DMADDM) coated dental implant [ | saliva-derived biofilm | inhibited biofilm growth and regulated microecosystem | |
| Bioactive antibacterial agents | Chitosan/P-HAP bi-layers coated titanium implant [ |
| Demonstrated an appropriate mouse pre-osteoblastic cell response, and significant anti-bacterial activity |
* The bacterial model were showed in abbreviated form: 1Pg, Porphyromonas gingivalis; 2Sg, Streptococcus gordonii; 3Aa, Aggregatibacter actinomycetemcomitan; 4 Ss, Streptococcus sanguinis; 5 E coli, Escherichia coli; 6 Sa, Staphylococcus aureus; 7 Sm, Streptococcus mutans; 8 Se, Staphylococcus epidermidis; 9 Fn, Fusobacterium nucleatum; 10 Pi, Prevotella intermedia.
Figure 6Recent DDS for oral candidiasis. (a) nystatin loaded lipid based nanoparticles, (b) clotrimazole loaded nanofiber mat; (c) Peptides loaded bioadhesive hydrogel; (d) modified denture materials with sustained drug release. The copolymer modified denture could had improved binding with miconazole and thus showed sustained drug release.
Figure 7Recent stimuli-responsive DDS in oral infectious diseases.